| Reagan-Udall Foundation

Read more about Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19.

Read more about Evaluation of MicroRNAs and Vitamin B12 Expression in Subjects with Neurologic Symptoms of Depression, Anxiety and Fatigue in Long COVID-19

Read more about A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to

Read more about Post COVID-19 Syndrome Treatment With Variable Pulse Transcranial Magnetic Stimulation

Read more about Relative Bioavailability Study of CX2101A for the Treatment of COVID-19

Read more about Enhancing Breastfeeding Self-Efficacy in Filipino Mothers: Assessing the Impact of the LactApp m-Health Tool

Read more about A Single-center, Interventional Diagnostic Study With Minimal Risks and Constraints, Aimed at Longitudinally Evaluating Serum Antibody Levels in Patients With COVID-19 According to the Severity of Their Symptoms.

Read more about A Study of CX2101A Enteric-Coated Tablets in Healthy Chinese Adult Subjects

Members of the consortium have had an ongoing dialogue with the hub, Critical Path Institute, the Reagan-Udall Foundation, and AMP ALS since mid-2024.

Coverage

Read more about BioCentury: The next rare disease roadblock: American innovation moving ex-U.S.

Read more about Primary Mitochondrial Diseases

The Reagan-Udall Foundation for the FDA, in collaboration with the Food and Drug Administration (FDA), hosted a virtual, public workshop to explore opportunities to optimize therapeutic development to address primary mitochondrial diseases.

Subscribe to

(202) 849 - 2075

1333 New Hampshire Ave, NW
Suite 420
Washington, DC 20036

admin@reaganudall.org

Subscribe for updates from the Reagan-Udall Foundation for the FDA